Drug Information

Drug General Information
Drug ID
D0O6IZ
Former ID
DAP001408
Drug Name
Naphazoline
Synonyms
Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole
Drug Type
Small molecular drug
Indication Corneal vascularity; Hyperaemia; Itching [ICD10:L29] Approved [551871]
Therapeutic Class
Anticancer Agents
Company
Allergan Inc
Structure
Download
2D MOL

3D MOL
Formula
C14H14N2
InChI
InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)
InChIKey
CNIIGCLFLJGOGP-UHFFFAOYSA-N
CAS Number
CAS 835-31-4
PubChem Compound ID
4436
PubChem Substance ID
3137457, 4405740, 7980082, 8152738, 10536779, 11112411, 11335631, 11342564, 11360870, 11363869, 11366431, 11368993, 11371665, 11373734, 11377155, 11461842, 11466074, 11467194, 11484744, 11485828, 11488870, 11490329, 11491883, 11494789, 14822445, 26751615, 29223533, 47291085, 47662225, 47810702, 47885358, 48035054, 48110408, 48110409, 49698318, 49980699, 50100430, 50810620, 57322271, 57937910, 85209585, 85788822, 88684032, 92244917, 92309071, 93624349, 96024941, 99443263, 103202876, 103916289
SuperDrug ATC ID
R01AA08; R01AB02; S01GA01
SuperDrug CAS ID
cas=000835314
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Agonist [534898]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 534898Decongestants in treatment of nasal obstruction. Otolaryngol Pol. 1999;53(3):347-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.